Search

Displaying results 7151 - 7160 of 10000 in total
  1. Drug

    2,5-di-tert-butylhydroquinone

    go.drugbank.com/drugs/DB04638
    Experimental

    Categories: Compounds used in a research, industrial, or household settingSynonyms: 2,5-di-tert-butylbenzene-1,4-diol
  2. Drug

    Hydrogenobyrinic acid

    go.drugbank.com/drugs/DB02460
    Experimental

    Categories: Heterocyclic Compounds with 4 or More Rings
  3. Drug

    IMC-1C11

    go.drugbank.com/drugs/DB06101
    Experimental

    IMC-1C11 is an anti-angiogenesis agent. … IMC-1C11 is used for treatment of patients with liver metastases from colorectal carcinoma.

  4. Drug

    VLTS-589

    go.drugbank.com/drugs/DB05430
    Investigational

    VLTS-589 consists of plasmid encoding the angiomatrix protein Del-1 in conjunction with poloxamer 188 for the treatment of peripheral vascular disease.

  5. Drug

    PRG-A01

    go.drugbank.com/drugs/DB18613
    Investigational

    PRG-A01 is a novel inhibitor of Cu, Zn-superoxide dismutase (SOD1) misfolding and aggregation.

  6. Drug

    Epratuzumab

    go.drugbank.com/drugs/DB04958
    Investigational

    This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as lupus. … Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monoclonal antibody, LL2 (EPB-2).

  7. Drug

    t-Butylhydroquinone

    go.drugbank.com/drugs/DB07726
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    2,3-Dimercapto-1-propanesulfonic acid

    go.drugbank.com/drugs/DB15967
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    LJ-2698

    go.drugbank.com/drugs/DB18018
    Experimental

    Categories: Adenosine A3 Receptor Antagonists
  10. Drug

    Laquinimod

    go.drugbank.com/drugs/DB06685
    Investigational

    It is currently under development in phase III trials for treatment of multiple sclerosis as an oral therapy, like fingolimod. … It has been shown to reduce disease activity on magnetic resonance imaging and to be well tolerated orally.